Cannabidiol gel ZYN002 for fragile X fails to meet goal in trial: Data
Use of CBD gel ZYN002 showed no greater effects vs. a placebo on social avoidance behavior in young people with fragile X syndrome in trial.| Fragile X News Today
Enrollment is complete in two Phase 2 clinical trials testing Ausperbio’s AHB-137 in people with chronic hepatitis B, the company said. That “positions us well as we move into the pivotal Phase III study of AHB-137, which was recently approved in China,” said Chris Yang, PhD, co-founder and chief scientific officer of Ausperbio, said in […] The post Enrollment complete in 2 Phase 2 trials testing hepatitis B treatment appeared first on Liver Disease News.| Liver Disease News – The Web's Daily Resource for Liver Disease News
Seven years after finishing treatment for stage 2 breast cancer, Valarie was devastated to learn she had metastatic breast cancer. “While my diagnosis is not curable, I continue to fight every day," she said. The post Valarie’s Story: Continuing to Fight Every Day appeared first on Susan G. Komen®.| Susan G. Komen®
Use of CBD gel ZYN002 showed no greater effects vs. a placebo on social avoidance behavior in young people with fragile X syndrome in trial.| Fragile X News Today
FDA approval for Stealth BioTherapeutics' elamipretide has been a long time coming. What does this mean for other ultra-rare disease companies? The post First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and l...| Labiotech.eu
The post The September 2025 <em>News from ECOG-ACRIN</em> blog is now available appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The first European participants in a Phase 2 trial of the Parkinson's gene therapy AB-1005 have been randomly assigned to treatment groups.| Parkinson's News Today
Rise Therapeutics plans to launch a Phase 1 clinical trial testing R-2487, its experimental oral therapy for autoimmune diseases, in people with Sjögren’s disease. R-2487, which leverages bacterial proteins to suppress the abnormal immune responses in autoimmune diseases like Sjögren’s, “is disease-modifying, focusing on long-term immune correction rather than short-term symptom relief,” Christian Furlan Freguia, […] The post Rise’s R-2487 moves toward clinical testing as Sjögr...| Sjogren's Disease News – The Web's Daily Resource for Sjogren's Disease News
The post Dr. Suzanne Cole on using real-world data to improve the generalizability of clinical trial results (highlights PrE1702 and EA5182) appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The post EA5181 trial finds no survival benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable non-small cell lung cancer appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
ENERGI-F705PD, a potential disease-modifying therapy for Parkinson’s, was found safe and well tolerated in healthy volunteers in a trial.| Parkinson's News Today
The post The August 2025 <em>News from ECOG-ACRIN</em> blog is now available appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The first three Parkinson's patients who received ANPD001 saw improvements in motor symptoms and daily functioning, early trial data showed.| Parkinson's News Today
After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in PH-ILD patients.| Pulmonary Hypertension News
Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly skin cancer.| Labiotech.eu
Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped capital.| Labiotech.eu
The first participants in a Phase 2 clinical trial testing brepocitinib, Roivant’s experimental oral treatment, in adults with cutaneous sarcoidosis have been dosed, and top-line results are expected in the second half […] The post Brepocitinib Phase 2 trial doses first cutaneous sarcoidosis patients appeared first on Sarcoidosis News.| Sarcoidosis News – The Web's Daily Resource for Sarcoidosis News
New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far along are they?| Labiotech.eu
Treatment with esketamine, a compound related to ketamine, led to some behavioral improvements in three girls with Rett syndrome in a trial.| Rett Syndrome News
When Kathryn Gallagher’s 13-year-old artificial heart valve started to fail, the oxygen-rich blood feeding her organs, tissues, and muscles slowed to a trickle. The condition, known as aortic valve stenosis, brought everything she loved doing to a standstill. The 80-year-old weightlifter and exercise junky could barely climb the stairs in her house without having to…| Kaiser Permanente Look insideKP Northern California
Zilbrysq was found safe and effective in a clinical trial for generalized myasthenia gravis patients who switched from other C5 inhibitors.| Myasthenia Gravis News
BioXcel plans to test BXCL501 for treating agitation in Alzheimer’s disease dementia in patients in nursing and assisted living facilities.| Alzheimer's News Today
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.| Pulmonary Fibrosis News
Target enrollment is complete for a Phase 1b trial testing the safety and tolerability of GT-02287 in people with Parkinson’s disease.| Parkinson's News Today
GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells to treat IPF.| Pulmonary Fibrosis News
Pending regulatory clearance in Colombia, Unravel Biosciences will launch a trial this summer testing Rett treatment RVL001 in 15 patients.| Rett Syndrome News
by Gertrud U. Rey The number of measles cases is steadily increasing across the United States, especially in areas with low vaccination rates. Instead of recommending that children be vaccinated with the measles, mumps, and rubella (MMR) vaccine, US Health and Human Services Secretary Robert F. Kennedy Jr. continues to promote ideas that are rooted …Vitamin A, Cod Liver Oil, and Measles Read More »| Virology Blog
Study Shows Plant Protein Shake Better for Blood Sugar Control than Dairy-Based Whey Full publication – Nutrients 2021 A study published June 23, 2021 in Nutrients aimed to look at the short-term effects on glycemic indices, gut hormones and subjective appetite ratings of two plant proteins (potato or rice) compared to an animal/dairy-based whey protein. [...] The post Study Shows Plant Protein Shake Better for Blood Sugar Control than Dairy-Based Whey appeared first on Axiom Foods.| Axiom Foods
The first four Rett syndrome patients treated with the gene therapy candidate NGN-401 have seen meaningful gains in skills, data show.| Rett Syndrome News
The Canadian government has cleared KGK Science's Phase 2a trial testing NM-1001, a psilocybin microdose therapy, in fragile X syndrome.| Fragile X News Today
Acupuncture is a form of alternative medicine that has been around for centuries, but a new study shows it could have a new use: preventing UTIs.| Scienceline
In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused pipelines.| Labiotech.eu
The first patient has been dosed in a Phase 2a trial of Parkinson's therapy VTX3232, an oral medication designed to reduce inflammation.| Parkinson's News Today
The FDA has approved a Phase 2 trial to test SPG601, an oral treatment candidate, in men with fragile X syndrome.| Fragile X News Today
Treatment with telitacicept for almost six months lessened disease activity in gMG adults positive for anti-AChR antibodies, per a study.| Myasthenia Gravis News
Iaso Bio has received clearance from the FDA to start clinical trials to test its CAR T-cell therapy equecabtagene autoleucel in MS patients.| Multiple Sclerosis News Today
Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio's spinout.| Labiotech.eu
The first patient was dosed in the U.S. as part of a clinical trial testing of NK cell therapy candidate AlloNK for lupus nephritis.| Lupus News Today
Seattle Children's will start a clinical trial testing CAR T-cell therapy in children with lupus this summer after getting FDA clearance.| Lupus News Today
Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years.| Labiotech.eu
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.| Labiotech.eu
